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Purpose: This study was conducted to examine whether simultaneous transrectal pros-
tate needle biopsy (TPNB) owing to an increase in prostate-specific antigen (PSA) levels 
is safe and effective in patients who are scheduled for transurethral resection of the 
prostate (TURP) for benign prostatic hyperplasia (BPH).
Materials and Methods: Combined TPNB and TURP was performed in a total of 42 pa-
tients aged 60 years and older who had gray-zone PSA values (4-10 ng/ml) and PSA 
density (PSAD) values of 0.12 and less. The frequencies of fever, sepsis, and epi-
didymitis were assessed after surgery. The diagnostic accuracy was assessed, and the 
results of histologic examination were evaluated in terms of TPNB or TURP. In addi-
tion, the diagnostic accuracy was assessed according to age.
Results: Prostate cancer was diagnosed in 6 (14.3%) of the 42 patients: 2 patients were 
diagnosed with prostate cancer by TPNB only, 3 patients by TURP only, and 1 patient 
by combined TPNB and TURP. Four (25%) of the 16 patients aged under 70 years and 
2 (7.8%) of the 26 patients aged 70 years and older were diagnosed with prostate cancer. 
Fever was observed in 9 patients (21.4%), 4 (9.5%) of whom had a fever of higher than 
38
oC . The fever normalized the day after surgery in all 9 patients. No septicemia was 
noted. There were no serious complications related to combined TPNB and TURP.
Conclusions: The results of this study suggest that combined TPNB and TURP may 
be safe and effective in patients who require TURP.
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INTRODUCTION
Prostate biopsy has been widely performed in clinical prac-
tice in patients with high prostate-specific antigen (PSA) 
levels, and the incidence of prostate cancer has increased. 
Although a serum PSA level of 3.0 or 4.0 ng/ml is used as 
a cutoff value for screening for prostate cancer, it is rela-
tively difficult to discriminate prostate cancer from benign 
prostatic hyperplasia (BPH) in men with gray-zone PSA 
values (4-10 ng/ml) [1,2]. To increase the diagnostic accu-
racy of prostate biopsy, various parameters including PSA 
velocity [3], percent free PSA [4], age reference PSA ranges 
[5], and PSA density (PSAD) [6] have been used in clinical 
practice. PSAD values of ≥0.15 are generally regarded as 
being highly suspicious of prostate cancer [7].
　With developments in prostate ultrasound and biopsy 
instruments, prostate biopsy can be performed under local 
anesthesia on an outpatient basis in most cases. The devel-
opment of prostate biopsy techniques has reduced patient 
discomfort, but a considerable number of patients still com-
plain of pain or discomfort [8]. Some patients refuse to un-
dergo prostate biopsy because they recall the pain of pre-
vious biopsy procedures [9]. To reduce this discomfort, 
prostate biopsy is sometimes performed under general an-
esthesia or spinal anesthesia, which is often costly and time 
consuming. In cases in which the PSA level is within the 
gray zone, but the PSAD value is low, this increased PSA 
level is mostly attributed to BPH, suggesting a lower possi-
bility of prostate cancer [10]. If combined prostate biopsy 
and transurethral resection of the prostate (TURP) is safe, 
the pain or discomfort experienced when prostate biopsy 
is performed separately can be avoided.
　This study was conducted to examine whether simulta-
neous transrectal prostate needle biopsy (TPNB) is safe Korean J Urol 2010;51:101-105
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TABLE 1. Patient characteristics (n=42)
Mean±SD
Age (years)
PSA (ng/ml)
Prostate volume (g)
PSA density (ng/ml/g)
Operative time (min)
Resected chip weight (g)
Postoperative catheterization (day)
Postoperative hospital stay (day)
71.3±5.7
6.0±2.0
75.9±27.7
0.084±0.026
73.6±34.1
32.4±21.6
2.6±0.8
5.5±1.6
PSA: prostate-specific antigen
TABLE 2. Clinico-pathological features of patients with prostate cancer detected in specimens from transurethral resection of the pros-
tate and/or transrectal needle biopsies
Patient
No.
Age
(years)
Prostate 
volume (g)
PSA
(ng/ml)
PSAD
Biopsy (Gleason score)
TURP Prostate biopsy
1
2
3
4
5
6
64
67
73
65
72
67
40.6
94.1
41.6
74.8
88.4
79.9
4.10
4.99
4.21
6.80
4.41
4.13
0.100
0.053
0.102
0.091
0.050
0.052
3＋4
3＋3
3＋3
−
−
3＋3
−
−
−
3＋4
3＋3
4＋3
PSA: prostate-specific antigen, PSAD: prostate-specific antigen density, TURP: transurethral resection of prostate
and effective in patients who are scheduled for TURP be-
cause of an increase in PSA levels.
MATERIALS AND METHODS
This study included a total of 42 patients aged ≥60 years 
who had PSA levels of 4 to 10 ng/ml and PSAD values of 
≤0.12 and who underwent combined TPNB and TURP at 
our hospital. The mean age, prostate volume, PSA level, 
and PSAD value of the patients were 71.3±5.7 years, 
75.9±27.7 g, 6.0±2.0 ng/ml, and 0.084±0.026, respectively 
(Table 1). PSA was measured by using the Tandem-R 
assay. Prostate volume was calculated by using the follow-
ing formula:
π/6xLxWxH
where L=length, W=width, and H=height. PSAD was cal-
culated by dividing PSA by prostate volume.
　After prostate biopsy was performed with the patient un-
der spinal anesthesia, the patient’s position was changed 
into the lithotomy position for TURP. Prostate biopsy was 
conducted under transrectal ultrasound guidance by using 
the 8 core method before February 2008 and the 12 core 
method after March 2008. After surgery, the degree and du-
ration of fever, the absence or presence of sepsis, and the 
development of complications, such as epididymitis or or-
chitis, were assessed. Fever was defined when the highest 
measurement was ≥37.5
oC. The diagnostic accuracy was 
determined, and the results of histological examinations 
were evaluated according to TPNB alone or combined 
TPNB and TURP. The Gleason score was measured in pa-
tients with a confirmed diagnosis of prostate cancer (PCa 
group). Clinical characteristics, prostate volume, PSA, and 
PSAD were analyzed in patients with a confirmed diag-
nosis of BPH (BPH group) and in the PCa group. Diagnostic 
accuracy was analyzed in two groups of patients according 
to age: those ＜70 years and those ≥70 years.
　All statistical analyses were performed by using SPSS 
12.0 (SPSS Inc, Chicago, USA). Comparisons of clinical 
characteristics and parameters were made by using the 
Mann-Whitney test. A p-value of ＜0.05 was considered 
significant.
RESULTS
The mean volume of the resected specimen after TURP was 
32.4±21.6 g. The durations of urethral catheter placement 
and admission were 2.6±0.8 and 5.5±1.6 days, respectively 
(Table 1). Of the total 42 patients, fever was noted in 9 pa-
tients (21.4%), 4 (9.5%) of whom had a fever of ≥38
oC. All 
of the 9 patients had fever the day after surgery, and the 
fever subsided within 24 hours. No patients had sepsis, per-
sistent hematospermia, orchitis, or epididymitis. There 
was no significant difference in the duration of hospital 
stay between the patients with fever and those without.
　Of the total 42 patients, 6 (14.3%) were definitively diag-
nosed as having prostate cancer. Prostate cancer was diag-
nosed in 2 patients by TPNB alone, in 3 patients by TURP 
alone, and in 1 patient by both procedures. The Gleason score 
was 6 points in 3 patients and 7 points in 3 patients (Table 2).
　The PSA level was 4.77 ng/ml in the PCa group and 6.22 
ng/ml in the BPH group, but the difference was not statisti-
cally significant. The PSAD value was 0.075 in the PCa 
group and 0.086 in the BPH group, but the difference was 
not statistically significant (Table 3). According to the ref-
erence age of 70 years, there were no significant differences 
in prostate volume, the PSA level, or the PSAD value be-
tween the two age groups of ＜70 years and ≥70 years. The 
diagnostic accuracy was 25.0% (4/16) in the patients aged 
＜70 years and 7.8% (2/26) in the patients aged ≥70 years 
(Table 4).Korean J Urol 2010;51:101-105
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TABLE 4. Comparison of patients aged ＜70 years and those aged ≥70 years 
＜70 years ≥70 years p-value
No. of patients (n=42)
Age (years)
Prostate volume (g)
PSA (ng/ml)
PSA density (ng/ml/g)
Cancer detection (%)
16 (38.0%)
65.6±2.53
71.06±19.40
5.89±1.95
0.087±0.029
4 (25.0)
26 (62.0%)
74.8±3.89
78.83±31.79
6.09±2.06
0.083±0.025
2 (7.8)
＜0.001
　0.613
　0.679
　0.604
PSA: prostate-specific antigen
TABLE 3. Comparison of patients with prostate cancer and patients with BPH
Prostate cancer BPH p-value
No. of patients (n=42)
Age (years)
Prostate volume (g)
PSA (ng/ml)
PSA density (ng/ml/g)
6
68.0±3.69
69.9±23.3
4.77±1.05
0.075±0.025
36
71.8±5.8
76.9±28.6
6.22±2.05
0.086±0.026
0.101
0.801
0.102
0.314
BPH: benign prostatic hyperplasia, PSA: prostate-specific antigen
DISCUSSION
With advancements in PSA screening tests, transrectal ul-
trasound, and biopsy instruments, prostate biopsy is wide-
ly performed in clinical practice. Although complications 
after prostate biopsy are not serious, many patients hesi-
tate to undergo prostate biopsy because of pain or 
discomfort. Zisman et al reported that about 96% and 89% 
of patients undergoing prostate biopsy complained of pain 
and discomfort, respectively [8]. Many attempts to reduce 
pain during prostate biopsy have been made. Among them, 
infusion of lidocaine jelly is simple to use but its effect is 
controversial [11]. A previous study documented that 
about 82% of patients reported “No” to the question “Will 
you undergo prostate biopsy again if needed?” [12]. When 
prostate biopsy is performed under general anesthesia to 
avoid such discomfort or pain, the procedure costs are in-
creased, although patient discomfort or pain can be 
reduced. Such problems can be solved if combined TPNB 
and TURP are performed in patients who need prostate bi-
opsy although there is a low possibility of prostate cancer 
based on a PSA level within the gray zone but a low PSAD 
value. Shen et al reported that combined TPNB and TURP 
is safe without notable complications other than fever, 
which agrees with our results [13]. Of the total 42 patients 
in the present study, 9 (21.4%) had fever after surgery, 4 
(9.5%) of whom had a fever of ≥38
oC. Fever subsided in all 
9 patients within 24 hours. There were no significant differ-
ences in the durations of urethral catheter placement and 
hospital stay between the patients with fever and those 
without fever. It has been reported that fever occurs in 4.4% 
or 6.2% of patients after TPNB alone [14,15]. In our study, 
a fever of ≥38
oC occurred in 9.5% of the patients without 
any significant difference between TPNB alone and com-
bined TPNB and TURP. Palisaar et al indicated that open 
radical retropubic prostatectomy after TURP gives favor-
able surgical and functional outcomes without an increase 
in the incidence of complications or sexual dysfunction [16]. 
In our study, open radical retropubic prostatectomy was 
performed on 5 of the 6 patients with a confirmed diagnosis 
of prostate cancer, and there was no increase in the in-
cidence of complications.
　PSAD is used to increase diagnostic accuracy in patients 
who have gray-zone PSA values (4-10 ng/ml). Some inves-
tigators have proposed that prostate biopsy is indicated for 
patients with a PSAD value of ≥0.15, and others have ad-
vocated that the criteria should be lowered. Gohji et al re-
ported that in a study of 287 patients with a PSA level of 
2.1-10.0 ng/ml, the PSA level had a sensitivity of 90%, a spe-
cificity of 36%, and a positive predictive value of 14% in 
those with a PSAD value of ＜0.12 [17]. A recent study 
showed that in patients with a PSA level of 4-10 ng/ml, the 
PSA level had a sensitivity of 90% and a specificity of 33.7% 
at a PSAD cutoff value of 0.134 [18]. In our study, combined 
TPNB and TURP was performed on patients with a PSA 
level of 4-10 ng/ml as well as a PSAD value of ＜0.12. As 
a result, 6 patients (14.6%) were definitively diagnosed 
with prostate cancer. Prostate cancer was diagnosed in 2 
patients (4.9) by TPNB alone, 3 patients (7.3%) by TURP 
alone, and 1 patient (2.4%) by combined TPNB and TURP. 
This result suggests that the diagnostic accuracy of TPNB 
alone is 7.3% in patients with a PSAD value of ＜0.12. It 
is generally recognized that TURP is effective in diagnos-
ing prostate cancer in patients with negative TPNB results 
[19,20]. Of the 6 patients diagnosed with prostate cancer, 
prostate cancer was definitively diagnosed by TURP in 4 
patients, 3 of whom were diagnosed by TURP alone. In oth-
er words, if TPNB alone had been performed on the afore-
mentioned 3 patients, the results might have been negative 
and the patients might have needed to undergo repeated Korean J Urol 2010;51:101-105
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TPNB or TURP. We were able to reduce the frequency of 
TPNB by combined TPNB and TURP. On the basis of these 
findings, we can infer that combined TPNB and TURP may 
be more effective than repeated TPNB in the diagnosis of 
prostate cancer in patients with previous TPNB-negative 
results.
　PSA tends to increase with age. The normal range of PSA 
has been reported to be 2.4-3.5 ng/ml in the 50 to 59 year 
group, 3.6-5.4 ng/ml in the 60 to 69 year group, and 5.2-7.5 
ng/ml in the 70 to 79 year group [21-24]. Therefore, it is esti-
mated that in elderly patients, the diagnostic accuracy of 
the PSA level may decrease in patients with low PSAD 
values. Meshref et al reported that the diagnostic accuracy 
of the PSA level in patients with a PSA level of 4.1-10 ng/ml 
was 0% in the 50 to 59 year group, 4.1% in the 60 to 69 year 
group, and 0% in the 70 to 79 year group at a PSAD cutoff 
value of 0.15 or less [25]. They also reported that the diag-
nostic accuracies of the PSA level were 4.2%, 1.5%, and 0%, 
respectively after adjustment for age (3.6-10 ng/ml for the 
50 to 59 year group, 4.6-10 ng/ml for the 60 to 69 year group, 
and 6.6-10 ng/ml for the 70 to 79 year group). Those authors 
concluded that the diagnostic accuracy of the PSA level was 
0% at a PSAD cutoff value of 0.15 or less in the ≥70 years 
age group. Kobayashi et al showed that diagnostic accuracy 
is low in patients aged ≥70 years with large prostate vol-
umes [10]. Thus, because the increased PSA level is prob-
ably due to BPH in the ≥70 years age group, prostate biop-
sy should be avoided in patients aged ≥70 years with large 
prostate volumes. Similarly, we found that the diagnostic 
accuracy of the PSA level was 25% and 8%, respectively, 
for the age groups of ＜70 and ≥70 years. Because there 
is a high possibility of the presence of diabetes mellitus or 
use of anticoagulant medications, the incidence of compli-
cations after TPNB may be high. In BPH patients aged ≥70 
years who are scheduled for TURP because they have a PSA 
level within the gray zone, separate TPNB can be avoided 
by performing combined TPNB and TURP.
　Our study had some limitations. First, it was retro-
spective in nature and the number of subjects was rela-
tively small. Second, even though TURP can enhance the 
diagnostic yield of prostate cancer in this group of patients, 
at the same time it could miss some chances of radical pros-
tatectomy without prior TURP. However, we confirmed 
that combined TPNB and TURP is safe and that the possi-
bility of prostate cancer may be reduced in elderly patients 
as found in previous studies.
CONCLUSIONS
Because combined TPNB and TURP is a safe procedure, it 
should be performed on patients who need the 2 pro-
cedures. In particular, this combined procedure may be 
useful for patients with TPNB-negative results who need 
TURP. Moreover, because there is a low possibility of pros-
tate cancer in BPH patients with a PSAD value of ＜0.12 
and aged more than 70 years old, combined TPNB and 
TURP can prevent unnecessary TPNB before TURP.
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